Propanc Biopharma, Inc. (PPCB)

NCM – Real vaqt narxi. Valyuta: USD

1.23

+0.06 (4.70%)

Bozor ochiq: Aug 12, 2026, 12:18 PM EDT

1.15

-0.02 (-1.66%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

12.08.2026

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and spread

06.08.2026

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and treatment-resistant solid tumors. In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, 3 times weekly intravenous PRP achieved: Greater than 90% mean tumor growth inhibition versus vehicle controls (p < 0.001) Marked reduction in metastatic burden in liver and peritoneum Significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition (EMT) markers Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, allowing lower chemotherapy doses while improving efficacy Median overall survival extension of more than 2.5-fold in treated animals compared with controls These results are built on previously reported >85% tumor growth inhibition data and peer-reviewed findings on PRP's impact on PDAC fibroblasts.

05.08.2026

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

MELBOURNE, Australia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it is completing the first tranche of $500,000 within the first 30 days since commencing its share repurchase program. “We will continue to honor our share repurchase program as we believe the Company is significantly undervalued as we progress to a world first, Phase 1b, First-In-Human study in 40 – 45 advanced cancer patients suffering from solid tumors, to be rolled out nationally in trial centers across Australia.

Videolar

No Data

There is no data to display

Press-relizlar

12.08.2026

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and spread

Propanc Biopharma, Inc. (PPCB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Videolar

No Data

Press-relizlar

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Videolar

No Data

Press-relizlar

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Search stocks

Propanc Biopharma, Inc. (PPCB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Videolar

No Data

Press-relizlar

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Videolar

No Data

Press-relizlar

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program